About VectivBio
VectivBio is a company based in Basel (Switzerland) founded in 2019 was acquired by Ironwood Pharma in May 2023. VectivBio has raised $145 million across 3 funding rounds from investors including Ironwood Pharma, TD Securities and Citadel. VectivBio has completed 1 acquisition, including Comet Therapeutics. VectivBio offers products and services including LINZESS and Pipeline Products. VectivBio operates in a competitive market with competitors including Phathom Pharmaceuticals, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Palisade Bio and Kamui Pharma, among others.
- Headquarter Basel, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$145 M (USD)
in 3 rounds
-
Latest Funding Round
$54 M (USD), Post-IPO
Jul 06, 2022
-
Investors
Ironwood Pharma
& 11 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Ironwood Pharma
(May 21, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VectivBio
VectivBio offers a comprehensive portfolio of products and services, including LINZESS and Pipeline Products.
Treats irritable bowel syndrome and chronic constipation.
Advances new therapies for gastrointestinal conditions.
People of VectivBio
Unlock access to complete
Unlock access to complete
Funding Insights of VectivBio
VectivBio has successfully raised a total of $145M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $54 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VectivBio
VectivBio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Ironwood Pharma, TD Securities and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for VectivBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VectivBio
VectivBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Comet Therapeutics.
Investment portfolio details for VectivBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Enzyme substitution therapy for neurological diseases is developed.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for VectivBio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - VectivBio
Detailed financials for VectivBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vectivbio Comparisons
Peer comparison for VectivBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VectivBio
VectivBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Phathom Pharmaceuticals, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Palisade Bio and Kamui Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals.
|
|
| Locked | Locked | Locked |
Second-generation probiotics are developed for gastrointestinal disorders.
|
|
| Locked | Locked | Locked |
Passionately pursuing better treatments for adults and children with rare liver diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal complications are developed by Palisade Bio.
|
|
| Locked | Locked | Locked |
Probiotic medicines for treating gastrointestinal diseases are developed.
|
Detailed competitors of VectivBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vectivbio
Complete news archive for VectivBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VectivBio
VectivBio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
VectivBio is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
VectivBio is a funded company, having raised a total of $145M across 3 funding rounds to date.
Developer of transformative therapeutics for rare diseases The lead product is Apraglutide which is a synthetic GLP-2 analog for the treatment of short bowel syndrome. It is designed to increase the intestines ability to absorb fluid and nutrients to minimize parenteral support and improve patient health.
VectivBio's top competitors include Phathom Pharmaceuticals, Palisade Bio and Lumena Pharma.
VectivBio offers LINZESS and Pipeline Products.
VectivBio has made 1 acquisition, including Comet Therapeutics.
VectivBio has 12 investors. Key investors include Ironwood Pharma, TD Securities, Citadel, Orbimed, and Bpifrance.